Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD

Exclusion Criteria

• •Recipient of umbilical cord blood stem cell graft.
• •Ongoing prednisone requirement greater than 1 mg/kg/day (or equivalent).
• •Karnofsky/Lansky performance score less than 40%.
• •Concurrent use of methotrexate, azathioprine, or a calcineurin-inhibitor plus sirolimus.
• •Other investigational agents within 4 weeks prior to enrollment.
• •Participants with post-transplant exposure to donor lymphocyte infusion, or T-cell or IL-2 targeted medications within 100 days prior to enrollment.
• •Participants with new immunosupprssive medication, extra-corporeal photopheresis or rituximab therapy initiated int he 4 weeks prior to enrollment.
• •Participants with active malignant relapse or recrudescence of their prior hematologic disorder.
• •Uncontrolled intercurrent illness unrelated to cGVHD.
• •Participants with psychiatric illness/social situations that would limit compliance with study requirements.
• •Pregnant patients are excluded.